Denosumab versus zoledronic acid: analgesic and survival impact of an extended treatment regimen beyond 2 years in breast cancer

Background: Zoledronic acid (ZA) and denosumab (Dmab) are the standard of care for bone metastases, but there is no consensus on their long-term use. This study was conducted to evaluate treatment patterns (persistence, compliance, modification, and reintroduction of drug therapy), analgesic efficac...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Ernesto Zecca, Luca Zambelli, Gabriele Tinè, Paola Bracchi, Rosalba Miceli, Alessandra Pigni, Silvia Lo Dico, Francesca Ricchini, Gabriella Mariani, Giacomo Massa, Augusto Caraceni
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2025-12-01
coleção:	Breast
Assuntos:	Long-term therapy Breast cancer Bone pain Denosumab Zoledronic acid Overall survival
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S0960977625006137
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!